

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)



(10) International Publication Number
WO 2021/159027 A1

(51) International Patent Classification:

A61K 38/21 (2006.01) A61P 31/14 (2006.01)
A61K 39/215 (2006.01) C07K 14/165 (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2021/016963

(22) International Filing Date:

05 February 2021 (05.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/971,194	06 February 2020 (06.02.2020)	US
63/017,614	29 April 2020 (29.04.2020)	US
63/021,552	07 May 2020 (07.05.2020)	US
63/091,881	14 October 2020 (14.10.2020)	US
63/093,334	19 October 2020 (19.10.2020)	US

(71) Applicant: **EIGER BIOPHARMACEUTICALS, INC.**
[US/US]; 2155 Park Boulevard, Palo Alto, California 94306 (US).

(72) Inventors: **GLENN, Jeffrey**; c/o Eiger Biopharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306 (US). **CHOONG, Ingrid**; c/o Eiger Biopharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306

(US). **HISLOP, Colin**; c/o Eiger Biopharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306 (US).

(74) Agent: **MOUSSA, Akkad Y.** et al.; KILPATRICK TOWNSEND & STOCKTON LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Eiger peg-IFN Lambda in HAE with SARS-CoV-2




FIG. 1

(57) Abstract: Methods of treating a coronavirus infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*